Clene Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Clene Inc. (CLNN) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$13.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-08-14
- Clene Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2026-06-30 was -$13.38M.
- Clene Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2026-03-31 was -$8.11M.
- Clene Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2025-12-31 was -$9.16M.
- Clene Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2025-09-30 was -$8.76M.
- Clene Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$26.00M.
- Clene Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$39.24M.
- Clene Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$48.58M.
- Clene Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$26.94M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 3 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 6 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 9 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$13.38M 10-Q · filed 2026-08-14 | -$21.48M 10-Q · filed 2026-08-14 | -$30.64M derived: sum of 3 quarters · filed 2026-08-14 | -$39.40M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$8.11M 10-Q · filed 2026-05-14 | -$17.26M derived: sum of 2 quarters · filed 2026-05-14 | -$26.02M derived: sum of 3 quarters · filed 2026-05-14 | -$33.40M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$9.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$17.91M derived: sum of 2 quarters · filed 2026-03-17 | -$25.30M derived: sum of 3 quarters · filed 2026-08-14 | -$26.00M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$8.76M 10-Q · filed 2025-11-13 | -$16.14M derived: sum of 2 quarters · filed 2026-08-14 | -$16.84M 10-Q · filed 2025-11-13 | -$30.36M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$7.38M 10-Q · filed 2026-08-14 | -$8.08M 10-Q · filed 2026-08-14 | -$21.60M derived: sum of 3 quarters · filed 2026-08-14 | -$29.54M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$701.00K 10-Q · filed 2026-05-14 | -$14.22M derived: sum of 2 quarters · filed 2026-05-14 | -$22.16M derived: sum of 3 quarters · filed 2026-05-14 | -$28.90M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$13.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$21.46M derived: sum of 2 quarters · filed 2026-03-17 | -$28.20M derived: sum of 3 quarters · filed 2026-03-17 | -$39.24M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$7.94M 10-Q · filed 2025-11-13 | -$14.68M derived: sum of 2 quarters · filed 2025-11-13 | -$25.72M 10-Q · filed 2025-11-13 | -$35.69M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$6.74M 10-Q · filed 2025-08-14 | -$17.78M 10-Q · filed 2025-08-14 | -$27.75M derived: sum of 3 quarters · filed 2025-08-14 | -$29.96M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$11.04M 10-Q · filed 2025-05-07 | -$21.01M derived: sum of 2 quarters · filed 2025-05-07 | -$23.21M derived: sum of 3 quarters · filed 2025-05-07 | -$48.07M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$9.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$12.18M derived: sum of 2 quarters · filed 2025-03-24 | -$37.03M derived: sum of 3 quarters · filed 2025-03-24 | -$48.58M 10-K · filed 2025-03-24 |
| 2023-09-30 | -$2.21M 10-Q · filed 2024-11-13 | -$27.06M derived: sum of 2 quarters · filed 2024-11-13 | -$38.61M 10-Q · filed 2024-11-13 | -$39.76M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$24.86M 10-Q · filed 2024-08-07 | -$36.40M 10-Q · filed 2024-08-07 | -$37.56M derived: sum of 3 quarters · filed 2024-08-07 | -$46.99M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$11.55M 10-Q · filed 2024-05-08 | -$12.70M derived: sum of 2 quarters · filed 2024-05-08 | -$22.13M derived: sum of 3 quarters · filed 2024-05-08 | -$25.53M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$10.59M derived: sum of 2 quarters · filed 2024-03-13 | -$13.98M derived: sum of 3 quarters · filed 2024-03-13 | -$26.94M 10-K · filed 2024-03-13 |
| 2022-09-30 | -$9.43M 10-Q · filed 2023-11-07 | -$12.83M derived: sum of 2 quarters · filed 2023-11-07 | -$25.79M 10-Q · filed 2023-11-07 | -$20.62M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$3.40M 10-Q · filed 2023-08-14 | -$16.36M 10-Q · filed 2023-08-14 | -$11.19M derived: sum of 3 quarters · filed 2023-08-14 | $18.67M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$12.96M 10-Q · filed 2023-05-12 | -$7.79M derived: sum of 2 quarters · filed 2023-05-12 | $22.07M derived: sum of 3 quarters · filed 2023-05-12 | $19.50M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $5.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $35.03M derived: sum of 2 quarters · filed 2023-03-13 | $32.45M derived: sum of 3 quarters · filed 2023-03-13 | -$6.27M 10-K · filed 2023-03-13 |
| 2021-09-30 | $29.86M 10-Q · filed 2022-11-07 | $27.29M derived: sum of 2 quarters · filed 2022-11-07 | -$11.44M 10-Q · filed 2022-11-07 | -$9.70M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$2.57M 10-Q · filed 2022-08-15 | -$41.30M 10-Q · filed 2022-08-15 | -$39.56M derived: sum of 3 quarters · filed 2022-08-15 | -$50.93M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$38.72M 10-Q · filed 2022-05-09 | -$36.98M derived: sum of 2 quarters · filed 2022-05-09 | -$48.35M derived: sum of 3 quarters · filed 2022-05-09 | -$54.32M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$9.63M derived: sum of 2 quarters · filed 2022-03-11 | -$15.60M derived: sum of 3 quarters · filed 2022-03-11 | -$18.98M 10-K · filed 2022-03-11 |
| 2020-09-30 | -$11.37M 10-Q · filed 2021-11-08 | -$17.34M derived: sum of 2 quarters · filed 2021-11-08 | -$20.72M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | -$5.97M 10-Q · filed 2021-08-09 | -$9.35M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$3.39M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | -$13.81M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |